Olema Pharmaceuticals
OLMA
73 hedge funds and large institutions have $101M invested in Olema Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 17 closing their positions.
622% more call options, than puts
Call options by funds: $231K | Put options by funds: $32K
6.17% more ownership
Funds ownership: 84.77% → 90.94% (+6.2%)
4% less funds holding
Funds holding: 76 → 73 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
27% less capital invested
Capital invested by funds: $139M → $101M (-$37.6M)
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$14.7M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$4.88M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.75M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$550K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$6.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.44M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.12M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$968K |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$952K |
OLMA Hedge Fund Activity: Q3 2022 in Review
73 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2022, worth a combined $101M — down 27% from $139M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of OLMA and 14 opened new positions — a net loss of 3 holders — while 24 trimmed existing stakes and 16 added.
The largest buyer was Janus Henderson Group, adding an estimated $14.7M. The largest seller was Fairmount Funds Management, cutting an estimated $6.1M.
- 73 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2022, down from 76 in Q2 2022.
- Funds reported $101M of Olema Pharmaceuticals stock for Q3 2022, down 27% quarter-over-quarter.
- 14 funds opened new Olema Pharmaceuticals positions in Q3 2022 and 17 closed out, a net change of -3 holders.
- The largest Olema Pharmaceuticals buyer in Q3 2022 was Janus Henderson Group, an estimated $14.7M added.
- The largest Olema Pharmaceuticals seller in Q3 2022 was Fairmount Funds Management, an estimated $6.1M sold.
Based on aggregated 13F filings for Q3 2022.